The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection
Open accessAbstract
Background The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents with a spectrum of clinical manifestations from asymptomatic or mild, self-limited constitutional symptoms to a hyperinflammatory state (“cytokine storm”) followed by acute respiratory distress syndrome (ARDS) and death. Objective To provide an evidence-based review of the associated pathways and potential treatment of the hyperinflammatory state associated with SARS-CoV-2 infection. Recent findings Dysregulated immune responses have been reported to occur in a smaller subset of those infected with SARS-CoV-2 leading to clinical deterioration 7 to 10 days following initial presentation. A hyperinflammatory state referred to as “cytokine storm” in its severest form has been marked by elevation of IL-6, IL-10, TNF-alpha and other cytokines and severe CD4+ and CD8+ T-cell lymphopenia and coagulopathy. Recognition of at-risk patients could permit early institution of aggressive intensive care, antiviral and immune treatment to reduce the complications related to this pro-inflammatory state. Several reports and ongoing clinical trials provide hope that available immunomodulatory therapies could have therapeutic potential in these severe cases. Conclusion This review highlights our current state of knowledge of immune mechanisms and targeted immunomodulatory treatment options for the current COVID-19 pandemic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0994 · Cited by 8,249
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Effective treatment of severe COVID-19 patients with tocilizumab
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,647
Channappanavar, R., & Perlman, S. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0629-x · Cited by 2,524
Hyperinflammatory shock in children during COVID-19 pandemic
Riphagen, S., Gomez, X., Gonzalez-Martinez, C., Wilkinson, N., & Theocharis, P. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31094-1 · Cited by 2,494
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., Li, M., Liu, Y., Wang, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00827 · Cited by 2,475
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
Merad, M., & Martin, J. C. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0331-4 · Cited by 2,472
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,277
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan
Li, X., Xu, S., Yu, M., Wang, K., Tao, Y., Zhou, Y., Shi, J., Zhou, M., Wu, B., Yang, Z., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.04.006 · Cited by 2,219
Into the Eye of the Cytokine Storm
Tisoncik, J. R., Korth, M. J., Simmons, C. P., Farrar, J., Martin, T. R., & Katze, M. G. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05015-11 · Cited by 1,940
Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia.
de Jong, M. D., Simmons, C. P., Thanh, T. T., Hien, V. M., Smith, G. J. D., Chau, T. N. B., Hoang, D. M., Van Vinh Chau, N., Khanh, T. H., Dong, V. C., et al. (2006) · Nature Medicine · doi:10.1038/nm1477 · Cited by 1,858
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785
Hung, I. F.-N., Lung, K.-C., Tso, E. Y.-K., Liu, R., Chung, T. W.-H., Chu, M.-Y., Ng, Y.-Y., Lo, J., Chan, J., Tam, A. R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31042-4 · Cited by 1,455
Activated STING in a Vascular and Pulmonary Syndrome
Liu, Y., Jesus, A. A., Marrero, B., Yang, D., Ramsey, S. E., Montealegre Sanchez, G. A., Tenbrock, K., Wittkowski, H., Jones, O. Y., Kuehn, H. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312625 · Cited by 1,412
Interleukin-17 and Type 17 Helper T Cells
Miossec, P., Korn, T., & Kuchroo, V. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0707449 · Cited by 1,409
Remdesivir for the Treatment of Covid-19 — Preliminary Report
(2020) · New England Journal of Medicine · doi:10.1056/nejmc2022236 · Cited by 1,396
Cytokine storm and sepsis disease pathogenesis
Chousterman, B. G., Swirski, F. K., & Weber, G. F. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0639-8 · Cited by 1,330
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients
Zhou, Y., Fu, B., Zheng, X., Wang, D., Zhao, C., Qi, Y., Sun, R., Tian, Z., Xu, X., & Wei, H. (2020) · National Science Review · doi:10.1093/nsr/nwaa041 · Cited by 1,295
Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome
WONG, C. K., LAM, C. W. K., WU, A. K. L., IP, W. K., LEE, N. L. S., CHAN, I. H. S., LIT, L. C. W., HUI, D. S. C., CHAN, M. H. M., CHUNG, S. S. C., et al. (2004) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2004.02415.x · Cited by 1,274
Zhang, W., Zhao, Y., Zhang, F., Wang, Q., Li, T., Liu, Z., Wang, J., Qin, Y., Zhang, X., Yan, X., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108393 · Cited by 1,266
Spread of SARS-CoV-2 in the Icelandic population
Gudbjartsson, D. F., Helgason, A., Jonsson, H., Magnusson, O. T., Melsted, P., Norddahl, G. L., Saemundsdottir, J., Sigurdsson, A., Sulem, P., Agustsdottir, A. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2006100 · Cited by 1,248
Li, L., Zhang, W., Hu, Y., Tong, X., Zheng, S., Yang, J., Kong, Y., Ren, L., Wei, Q., Mei, H., et al. (2020) · JAMA · doi:10.1001/jama.2020.10044 · Cited by 1,206
Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19
Herold, T., Jurinovic, V., Arnreich, C., Lipworth, B. J., Hellmuth, J. C., von Bergwelt-Baildon, M., Klein, M., & Weinberger, T. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.008 · Cited by 1,161
Pedersen, S. F., & Ho, Y.-C. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137647 · Cited by 1,137
COVID-19, SARS and MERS: are they closely related?
Petrosillo, N., Viceconte, G., Ergonul, O., Ippolito, G., & Petersen, E. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.03.026 · Cited by 1,108
Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China
Wang, Z., Yang, B., Li, Q., Wen, L., & Zhang, R. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa272 · Cited by 1,063
Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID‐19
Gao, Y., Li, T., Han, M., Li, X., Wu, D., Xu, Y., Zhu, Y., Liu, Y., Wang, X., & Wang, L. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25770 · Cited by 1,047
Convalescent plasma as a potential therapy for COVID-19
Chen, L., Xiong, J., Bao, L., & Shi, Y. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30141-9 · Cited by 1,038
Chen, X., Zhao, B., Qu, Y., Chen, Y., Xiong, J., Feng, Y., Men, D., Huang, Q., Liu, Y., Yang, B., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa449 · Cited by 1,020
Cavalli, G., De Luca, G., Campochiaro, C., Della-Torre, E., Ripa, M., Canetti, D., Oltolini, C., Castiglioni, B., Tassan Din, C., Boffini, N., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30127-2 · Cited by 970
Use of convalescent plasma therapy in SARS patients in Hong Kong
Cheng, Y., Wong, R., Soo, Y. O. Y., Wong, W. S., Lee, C. K., Ng, M. H. L., Chan, P., Wong, K. C., Leung, C. B., & Cheng, G. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1271-9 · Cited by 958
HARBARTH, S., HOLECKOVA, K., FROIDEVAUX, C., PITTET, D., RICOU, B., GRAU, G. E., VADAS, L., PUGIN, J., & the Geneva Sepsis Network (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.3.2009052 · Cited by 898
Le, R. Q., Li, L., Yuan, W., Shord, S. S., Nie, L., Habtemariam, B. A., Przepiorka, D., Farrell, A. T., & Pazdur, R. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0028 · Cited by 873
Shakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001402 · Cited by 867
Jones, A. E., Trzeciak, S., & Kline, J. A. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e31819def97 · Cited by 850
Kellum, J. A. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.15.1655 · Cited by 828
Deployment of convalescent plasma for the prevention and treatment of COVID-19
Bloch, E. M., Shoham, S., Casadevall, A., Sachais, B. S., Shaz, B., Winters, J. L., van Buskirk, C., Grossman, B. J., Joyner, M., Henderson, J. P., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138745 · Cited by 799
Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N., & Kakehi, T. (2008) · Blood · doi:10.1182/blood-2008-05-155846 · Cited by 795
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
Wu, D., & Yang, X. O. (2020) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2020.03.005 · Cited by 785
COVID-19 and Kawasaki Disease: Novel Virus and Novel Case
Jones, V. G., Mills, M., Suarez, D., Hogan, C. A., Yeh, D., Segal, J. B., Nguyen, E. L., Barsh, G. R., Maskatia, S., & Mathew, R. (2020) · Hospital Pediatrics · doi:10.1542/hpeds.2020-0123 · Cited by 766
Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing
Wen, W., Su, W., Tang, H., Le, W., Zhang, X., Zheng, Y., Liu, X., Xie, L., Li, J., Ye, J., et al. (2020) · Cell Discovery · doi:10.1038/s41421-020-0168-9 · Cited by 730
An interferon‐γ‐related cytokine storm in SARS patients
Huang, K., Su, I., Theron, M., Wu, Y., Lai, S., Liu, C., & Lei, H. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20255 · Cited by 679
Chu, H., Chan, J. F.-W., Wang, Y., Yuen, T. T.-T., Chai, Y., Hou, Y., Shuai, H., Yang, D., Hu, B., Huang, X., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa410 · Cited by 667
Faix, J. D. (2013) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2013.764490 · Cited by 663
Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis
Gralinski, L. E., Sheahan, T. P., Morrison, T. E., Menachery, V. D., Jensen, K., Leist, S. R., Whitmore, A., Heise, M. T., & Baric, R. S. (2018) · mBio · doi:10.1128/mbio.01753-18 · Cited by 655
Wan, S., Yi, Q., Fan, S., Lv, J., Zhang, X., Guo, L., Lang, C., Xiao, Q., Xiao, K., Yi, Z., et al. (2020) · doi:10.1101/2020.02.10.20021832 · Cited by 562
Haga, S., Yamamoto, N., Nakai-Murakami, C., Osawa, Y., Tokunaga, K., Sata, T., Yamamoto, N., Sasazuki, T., & Ishizaka, Y. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711241105 · Cited by 521
Convalescent plasma in Covid-19: Possible mechanisms of action
Rojas, M., Rodríguez, Y., Monsalve, D. M., Acosta-Ampudia, Y., Camacho, B., Gallo, J. E., Rojas-Villarraga, A., Ramírez-Santana, C., Díaz-Coronado, J. C., Manrique, R., et al. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102554 · Cited by 491
Saad, M., Omrani, A. S., Baig, K., Bahloul, A., Elzein, F., Matin, M. A., Selim, M. A. A., Mutairi, M. A., Nakhli, D. A., Aidaroos, A. Y. A., et al. (2014) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2014.09.003 · Cited by 486
Complement as a target in COVID-19?
Risitano, A. M., Mastellos, D. C., Huber-Lang, M., Yancopoulou, D., Garlanda, C., Ciceri, F., & Lambris, J. D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0320-7 · Cited by 484
Interleukin-6: A Masterplayer in the Cytokine Network
Uciechowski, P., & Dempke, W. C. M. (2020) · Oncology · doi:10.1159/000505099 · Cited by 465
Cao, Y., Wei, J., Zou, L., Jiang, T., Wang, G., Chen, L., Huang, L., Meng, F., Huang, L., Wang, N., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.019 · Cited by 456
Dysregulation of type I interferon responses in COVID-19
Acharya, D., Liu, G., & Gack, M. U. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0346-x · Cited by 454
Pathogenesis of Macrophage Activation Syndrome and Potential for Cytokine- Directed Therapies
Schulert, G. S., & Grom, A. A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-061813-012806 · Cited by 402
Zhang, D., Guo, R., Lei, L., Liu, H., Wang, Y., Wang, Y., Qian, H., Dai, T., Zhang, T., Lai, Y., et al. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.4hi0720-470r · Cited by 383
Trends in Mortality for Medicare Beneficiaries Treated in the Emergency Department From 2009 to 2016
Burke, L. G., Epstein, S. K., Burke, R. C., Orav, E. J., & Jha, A. K. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.4866 · Cited by 382
Soo, Y. O. Y., Cheng, Y., Wong, R., Hui, D. S., Lee, C. K., Tsang, K. K. S., Ng, M. H. L., Chan, P., Cheng, G., & Sung, J. J. Y. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00956.x · Cited by 381
The Biology and Medical Implications of Interleukin-6
Tanaka, T., & Kishimoto, T. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0022 · Cited by 375
Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review
Rajendran, K., Krishnasamy, N., Rangarajan, J., Rathinam, J., Natarajan, M., & Ramachandran, A. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25961 · Cited by 360
Song, J., Park, D. W., Moon, S., Cho, H.-J., Park, J. H., Seok, H., & Choi, W. S. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4618-7 · Cited by 348
Analysis of Serum Cytokines in Patients with Severe Acute Respiratory Syndrome
Zhang, Y., Li, J., Zhan, Y., Wu, L., Yu, X., Zhang, W., Ye, L., Xu, S., Sun, R., Wang, Y., et al. (2004) · Infection and Immunity · doi:10.1128/iai.72.8.4410-4415.2004 · Cited by 338
Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era
Behrens, E. M., & Koretzky, G. A. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40071 · Cited by 304
Interleukin‐6 Trans‐Signalling in Chronic Inflammation and Cancer
Scheller, J., Ohnesorge, N., & Rose‐John, S. (2006) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2006.01750.x · Cited by 297
Histiocytic Disorders: Recent Insights into Pathophysiology and Practical Guidelines
Filipovich, A., McClain, K., & Grom, A. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.11.014 · Cited by 294
Miettunen, P. M., Narendran, A., Jayanthan, A., Behrens, E. M., & Cron, R. Q. (2011) · Rheumatology · doi:10.1093/rheumatology/keq218 · Cited by 284
The Middle East Respiratory Syndrome (MERS)
Azhar, E. I., Hui, D. S. C., Memish, Z. A., Drosten, C., & Zumla, A. (2019) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2019.08.001 · Cited by 278
Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity
Weber, A. N. R., Bittner, Z., Liu, X., Dang, T.-M., Radsak, M. P., & Brunner, C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01454 · Cited by 269
Will Complement Inhibition Be the New Target in Treating COVID-19–Related Systemic Thrombosis?
Campbell, C. M., & Kahwash, R. (2020) · Circulation · doi:10.1161/circulationaha.120.047419 · Cited by 267
Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis
Pettilä, V., Hynninen, M., Takkunen, O., Kuusela, P., & Valtonen, M. (2002) · Intensive Care Medicine · doi:10.1007/s00134-002-1416-1 · Cited by 214
IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review
Ogata, A., Kato, Y., Higa, S., & Yoshizaki, K. (2019) · Modern Rheumatology · doi:10.1080/14397595.2018.1546357 · Cited by 211
Spencer, S., Köstel Bal, S., Egner, W., Lango Allen, H., Raza, S. I., Ma, C. A., Gürel, M., Zhang, Y., Sun, G., Sabroe, R. A., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20190344 · Cited by 205
Price, C. C., Altice, F. L., Shyr, Y., Koff, A., Pischel, L., Goshua, G., Azar, M. M., Mcmanus, D., Chen, S.-C., Gleeson, S. E., et al. (2020) · Chest · doi:10.1016/j.chest.2020.06.006 · Cited by 204
Procalcitonin as a diagnostic marker and IL-6 as a prognostic marker for sepsis
Jekarl, D. W., Lee, S.-Y., Lee, J., Park, Y.-J., Kim, Y., Park, J. H., Wee, J. H., & Choi, S. P. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.12.011 · Cited by 181
Maier, B., Lefering, R., Lehnert, M., Laurer, H. L., Steudel, W. I., Neugebauer, E. A., & Marzi, I. (2007) · Shock · doi:10.1097/shk.0b013e318123e64e · Cited by 173
Schulert, G. S., Zhang, M., Fall, N., Husami, A., Kissell, D., Hanosh, A., Zhang, K., Davis, K., Jentzen, J. M., Napolitano, L., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv550 · Cited by 170
Macrophage activation syndrome and cytokine-directed therapies
Schulert, G. S., & Grom, A. A. (2014) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2014.03.002 · Cited by 163
Ma, L., Zhang, H., Yin, Y., Guo, W.-Z., Ma, Y., Wang, Y.-B., Shu, C., & Dong, L.-Q. (2016) · Cytokine · doi:10.1016/j.cyto.2016.08.033 · Cited by 163
Gouél‐Cheron, A., Allaouchiche, B., Guignant, C., Turrel-Davin, F., Floccard, B., Monneret, G., & for AzuRea Group (2012) · PLoS ONE · doi:10.1371/journal.pone.0033095 · Cited by 143
Zhang, X., Wu, K., Wang, D., Yue, X., Song, D., Zhu, Y., & Wu, J. (2007) · Virology · doi:10.1016/j.virol.2007.04.009 · Cited by 141
Clinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea
Choi, W. S., Kang, C., Kim, Y., Choi, J., Joh, J.-S., Shin, H., Kim, G., Peck, K. R., Chung, D. R., Kim, H. O., et al. (2016) · Infection and Chemotherapy · doi:10.3947/ic.2016.48.2.118 · Cited by 135
The early IL‐6 and IL‐10 response in trauma is correlated with injury severity and mortality
Stensballe, J., Christiansen, M., Tønnesen, E., Espersen, K., Lippert, F. K., & Rasmussen, L. S. (2009) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.2008.01801.x · Cited by 133
Serial cytokine levels in patients with severe sepsis
Wu, H.-P., Chen, C.-K., Chung, K., Tseng, J., Hua, C., Liu, Y., Chuang, D., & Yang, C.-H. (2009) · Inflammation Research · doi:10.1007/s00011-009-0003-0 · Cited by 129
COVID-19–Associated Pediatric Multisystem Inflammatory Syndrome
Leon, M. D., Redzepi, A., McGrath, E. J., Abdel‐Haq, N., Shawaqfeh, A., Sethuraman, U., Tilford, B., Chopra, T., Arora, H. S., Ang, J. Y., et al. (2020) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piaa061 · Cited by 126
ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer
Schumacher, N., & Rose‐John, S. (2019) · Cancers · doi:10.3390/cancers11111736 · Cited by 112
The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis
Cohen, S. B. (2004) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2004.01.005 · Cited by 104
Billeter, A. T., Turina, M., Seifert, B., Mica, L., Stocker, R. A., & Keel, M. J. B. (2009) · World Journal of Surgery · doi:10.1007/s00268-008-9896-y · Cited by 98
Beutel, G., Wiesner, O., Eder, M., Hafer, C., Schneider, A. S., Kielstein, J. T., Kühn, C., Heim, A., Ganzenmueller, T., Kreipe, H.-H., et al. (2011) · Critical Care · doi:10.1186/cc10073 · Cited by 95
Chalmers, S. J., Khawaja, A. I., Wieruszewski, P. M., Gajic, O., & Odeyemi, Y. (2019) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v8.i5.74 · Cited by 93
Interleukin-6 blockade for severe COVID-19Preprint
Roumier, M., Paule, R., Groh, M., Vallée, A., Ackermann, F., & for the Foch COVID-19 Study Group (2020) · medRxiv · doi:10.1101/2020.04.20.20061861 · Cited by 92
Uusitalo‐Seppälä, R., Koskinen, P. J., Leino, A. E., Peuravuori, H. J., Vahlberg, T. J., & Rintala, E. M. (2011) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2011.600325 · Cited by 91
Nor, M. B. M., Ralib, A. M., Abdulah, N. Z., & Pickering, J. W. (2016) · Journal of Critical Care · doi:10.1016/j.jcrc.2016.01.002 · Cited by 88
Takahashi, W., Nakada, T., Yazaki, M., & Oda, S. (2016) · Shock · doi:10.1097/shk.0000000000000616 · Cited by 88
OʼBrien, T. R., Thomas, D. L., Jackson, S. S., Prokunina‐Olsson, L., Donnelly, R. P., & Hartmann, R. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa453 · Cited by 88
STAT3 inhibition enhances CDN-induced STING signaling and antitumor immunity
Pei, J., Zhang, Y., Luo, Q., Zheng, W., Li, W., Zeng, X. Y., Li, Q., & Quan, J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.02.029 · Cited by 75
Kumar, B., Aleem, S., Saleh, H., Petts, J., & Ballas, Z. K. (2017) · Journal of Clinical Immunology · doi:10.1007/s10875-017-0439-x · Cited by 73
Muñoz-Bermúdez, R., Abella, E., Zuccarino, F., Masclans, J. R., & Nolla‐Salas, J. (2019) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v8.i5.59 · Cited by 61
Adam, N., Rabe, B., Suthaus, J., Grötzinger, J., Rose‐John, S., & Scheller, J. (2009) · Journal of Virology · doi:10.1128/jvi.01601-08 · Cited by 57
Influence of gender on systemic IL-6 levels, complication rates and outcome after major trauma
Mörs, K., Braun, O., Wagner, N., Auner, B., Voth, M., Störmann, P., Wutzler, S., Marzi, İ., & Relja, B. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.03.005 · Cited by 46
Fala, L. (2016) · Europe PMC (PubMed Central) · Cited by 35
Klaver, Y., van Steenbergen, S. C. L., Sleijfer, S., Debets, R., & Lamers, C. H. J. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.06.014 · Cited by 11
Cited by
Szabo, P. A., Dogra, P., Gray, J. I., Wells, S. B., Connors, T. J., Weisberg, S. P., Krupska, I., Matsumoto, R., Poon, M. M. L., Idzikowski, E., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.005 · Cited by 383
Role of Inflammatory Cytokines, Growth Factors and Adipokines in Adipogenesis and Insulin Resistance
Al-Mansoori, L., Al-Jaber, H., Prince, M. S., & Elrayess, M. A. (2022) · Inflammation · doi:10.1007/s10753-021-01559-z · Cited by 285
Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19
Li, X., Zhang, Z., Wang, Z., Gutiérrez-Castrellón, P., & Shi, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01043-6 · Cited by 67
RNA-guided cell targeting with CRISPR/RfxCas13d collateral activity in human cells
Shi, P., Murphy, M. R., Aparicio, A. O., Kesner, J. S., Fang, Z., Chen, Z., Trehan, A., & Wu, X. (2021) · doi:10.1101/2021.11.30.470032 · Cited by 21
Metadata
- Authors
- Copaescu, A., Smibert, O., Gibson, A., Phillips, E. J., & Trubiano, J. A.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 146
- Issue
- 3
- Pages
- 518-534.e1
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W3081790187
- Cited by
- 262
- References
- 112
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.